Recent achievements in molecular insights, anticancer activities, and comparative structure activity relationships of thiazolidin-4-one derivatives as EGFR inhibitors (2019-present).

The EGFR family is considered one of the most important receptor tyrosine kinases. The family consists of four main members: EGFR, HER2, ErbB3, and ErbB4. They have a crucial role in cancer progression and growth, especially in solid tumors such as lung, breast, colon, neck, and brain tumors. Since the first member, EGFR, is highly incorporated in several pathways regarding cancer, we provide a comparative understanding of all FDA-approved drugs targeting EGFR, demonstrating their structures' developments to provide a good illustration of possible EGFR binding interactions. From the recently approved drugs, we selected our nucleus for study, which is the thiazolidin-4-one nucleus. The review aims to provide an overview of all recent EGFR TK inhibitors bearing this nucleus with additional demonstrations of their structure-activity relationships gathering all those SARs into a general one. A comprehensive understanding of SARs of recent thiazolidin-4-one derivatives may inspire others to develop new, potent, and selective drugs targeting EGFR.

• Publication year

  2025

• Venue

  Bioorganic & Medicinal Chemistry

• Publication date

  2025-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmc.2025.118244PMID 40513224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021–Present)

  2024cited by this paper
• Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial.

  2024cited by this paper
• New thiazolidin-4-ones as anti-cervical cancer agents targeting EGFR: design, synthesis, and computational studies.

  2024cited by this paper
• Synthesis, Characterization and Anticancer Investigation of some Novel 2,5-disubstituted-1,3-thiazol-4-(5H)-ones and 1-substituted-1H-pyrazolo[3,4-d] thiazole derivatives

  2024cited by this paper
• Medicinal Perspective of 2,4‐Thiazolidinediones Derivatives: An Insight into Recent Advancements

  2024cited by this paper
• Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challenges

  2024cited by this paper
• S-Heterocycles: Synthesis and Biological Evaluation

  2024cited by this paper
• Anticancer Potential of the S‐Heterocyclic Ring Containing Drugs and its Bioactivation to Reactive Metabolites

  2024cited by this paper
• Thiazolidinedione an Auspicious Scaffold as PPAR-γ Agonist: its Possible Mechanism to Manoeuvre against Insulin Resistant Diabetes Mellitus.

  2024cited by this paper
• Design, synthesis, biological assessment and molecular modeling studies of novel imidazothiazole-thiazolidinone hybrids as potential anticancer and anti-inflammatory agents

  2024cited by this paper
• New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study

  2023cited by this paper
• Lobeglitazone and Its Therapeutic Benefits: A Review

  2023cited by this paper
• Synthesis and Antiproliferative Potential of Thiazole and 4-Thiazolidinone Containing Motifs as Dual Inhibitors of EGFR and BRAFV600E

  2023cited by this paper
• The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)

  2023cited by this paper
• Phenylthiazolidin-4-one Piperazine Conjugates: Design, Synthesis, Anticancer and Antimicrobial Studies

  2023cited by this paper
• New pyrazolyl-thiazolidinone/thiazole derivatives as celecoxib/dasatinib analogues with selective COX-2, HER-2 and EGFR inhibitory effects: design, synthesis, anti-inflammatory/anti-proliferative activities, apoptosis, molecular modelling and ADME studies

  2023cited by this paper
• Anticancer Studies of Newly Synthesized Thiazole Derivatives: Synthesis, Characterization, Biological Activity, and Molecular Docking

  2023cited by this paper
• Recent insights into synthesis, biological activities, structure activity relationship and molecular interactions of thiazolidinone hybrids: A systematic review

  2023cited by this paper
• Rational design and eco-friendly one-pot multicomponent synthesis of novel ethylidenehydrazineylthiazol-4(5H)-ones as potential apoptotic inducers targeting wild and mutant EGFR-TK in triple negative breast cancer.

  2023cited by this paper
• Rational design and synthesis of novel quinazolinone N-acetohydrazides as type II multi-kinase inhibitors and potential anticancer agents.

  2023cited by this paper
• Novel Pyridine-Thiazolidinone-Triazole Hybrid Glycosides Targeting EGFR and CDK-2: Design, Synthesis, Anticancer Evaluation, and Molecular Docking Simulation

  2023cited by this paper
• Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer

  2023cited by this paper
• Designing strategies, structural activity relationship and biological activity of recently developed nitrogen containing heterocyclic compounds as epidermal growth factor receptor tyrosinase inhibitors

  2023cited by this paper
• Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review

  2023cited by this paper
• Insights from the molecular docking analysis of EGFR antagonists

  2023cited by this paper
• One-Pot Synthesis of 1-Thia-4-azaspiro[4.4/5]alkan-3-ones via Schiff Base: Design, Synthesis, and Apoptotic Antiproliferative Properties of Dual EGFR/BRAFV600E Inhibitors

  2023cited by this paper
• Pharmacokinetic profiling of quinazoline-4(3H)-one analogs as EGFR inhibitors: 3D-QSAR modeling, molecular docking studies and the design of therapeutic agents

  2023cited by this paper
• Synthesis, characterization, molecular docking and in vitro anti-cancer activity studies of new and highly selective 1,2,3-triazole substituted 4-hydroxybenzohyrdazide derivatives

  2023cited by this paper
• Anticancer Potential of Compounds Bearing Thiazolidin-4-one Scaffold: Comprehensive Review

  2023cited by this paper
• Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities

  2023cited by this paper
• Thiazolidin-4-one-based derivatives - Efficient tools for designing antiprotozoal agents. A review of the last decade.

  2023cited by this paper
• Design, synthesis, docking, and mechanistic studies of new thiazolyl/thiazolidinylpyrimidine-2,4-dione antiproliferative agents

  2023cited by this paper
• Thiazolidinone‐Heterocycle Frameworks: A Concise Review of Their Pharmacological Significance

  2023cited by this paper
• Synthesis, Characterization, and Pharmacokinetic Studies of Thiazolidine-2,4-Dione Derivatives

  2023cited by this paper
• Screening of 1,3,4-Thiadiazole Derivatives by in silico Molecular Docking to Target Estrogen Receptor for Breast Cancer

  2022cited by this paper
• Heterocyclic compounds: Importance in anticancer drug discovery.

  2022cited by this paper
• Thiazolidin-4-Ones as Potential Antimicrobial Agents: Experimental and In Silico Evaluation

  2022cited by this paper
• The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC.

  2022cited by this paper
• Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy.

  2022cited by this paper
• One-Pot Synthesis of Novel 2-Imino-5-Arylidine-Thiazolidine Analogues and Evaluation of Their Anti-Proliferative Activity against MCF7 Breast Cancer Cell Line

  2022cited by this paper
• 4-Thiazolidinone-Bearing Hybrid Molecules in Anticancer Drug Design

  2022cited by this paper
• Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study)

  2022cited by this paper
• A review on biological and medicinal impact of heterocyclic compounds

  2022cited by this paper
• Thiazolidin-2,4-Dione Scaffold: An Insight into Recent Advances as Antimicrobial, Antioxidant, and Hypoglycemic Agents

  2022cited by this paper
• Design, Synthesis, Crystal Structures and Biloigical Evaluation of Some 1,3-Thiazolidin-4-ones as Dual CDK2/EGFR Potent Inhibitors with Potential Apoptotic Antiproliferative Effects

  2022cited by this paper
• Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights

  2022cited by this paper
• A Review on Medicinally Important Heterocyclic Compounds

  2022cited by this paper
• Design and synthesis of new thiazolidinone/uracil derivatives as antiproliferative agents targeting EGFR and/or BRAFV600E

  2022cited by this paper
• Successful Dasatinib Treatment of Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma and BCR-ABL1-Positive Chronic Myeloid Leukemia: A Case Report

  2022cited by this paper
• Design, synthesis, in vitro biological assessment and molecular modeling insights for novel 3-(naphthalen-1-yl)-4,5-dihydropyrazoles as anticancer agents with potential EGFR inhibitory activity

  2022cited by this paper
• Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus

  2021cited by this paper
• Design, Synthesis and Assessment of new series of Quinazolinone Derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines.

  2021cited by this paper
• Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR.

  2021cited by this paper
• Synthesis and biological evaluation of new derivatives of thieno-thiazole and dihydrothiazolo-thiazole scaffolds integrated with a pyrazoline nucleus as anticancer and multi-targeting kinase inhibitors

  2021cited by this paper
• Furazans in Medicinal Chemistry.

  2021cited by this paper
• Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

  2021cited by this paper
• Quinoline‐based thiazolidinone derivatives as potent cytotoxic and apoptosis‐inducing agents through EGFR inhibition

  2021cited by this paper
• The JAK/STAT signaling pathway: from bench to clinic

  2021cited by this paper
• Thiazolidinone: A Structural Motif of Great Synthetic and Biological Importance

  2021cited by this paper
• Synthesis, Characterization and Anti-corrosion Activity of New Triazole, Thiadiazole and Thiazole Derivatives Containing Imidazo[1,2-a]pyrimidine Moiety

  2021cited by this paper
• EGFR-RAS-MAPK signaling is confined to the plasma membrane and associated endorecycling protrusions

  2021cited by this paper
• Synthesis of new 2-(thiazol-4-yl)thiazolidin-4-one derivatives as potential anti-mycobacterial agents.

  2021cited by this paper
• New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies.

  2021cited by this paper
• EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance

  2021cited by this paper
• Synthesis of novel coumarin-thiazolidine-2,4-dione derivatives: An approach to computational studies and biological evaluation

  2021cited by this paper
• Design, synthesis and molecular docking of new pyrazole-thiazolidinones as potent anti-inflammatory and analgesic agents with TNF-α inhibitory activity.

  2021cited by this paper
• Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study

  2020cited by this paper
• Dual Inhibition of EGFR and BRAF Can Be Harmful in Patients Harboring an EGFR-Activating Mutation.

  2020cited by this paper
• An overview on medicinal perspective of thiazolidine-2,4-dione: A remarkable scaffold in the treatment of type 2 diabetes

  2020cited by this paper
• Saturated Five-Membered Thiazolidines and Their Derivatives: From Synthesis to Biological Applications

  2020cited by this paper
• Thiazoles, Their Benzofused Systems, and Thiazolidinone Derivatives: Versatile and Promising Tools to Combat Antibiotic Resistance

  2020cited by this paper
• Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?

  2020cited by this paper
• Synthesis and Biological Activity of Some New Thiazolidinone Derivatives

  2020cited by this paper
• Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings

  2020cited by this paper
• Design, synthesis, and biological evaluation of imidazopyridine‐linked thiazolidinone as potential anticancer agents

  2020cited by this paper
• New Paracyclophanylthiazoles with Anti-Leukemia Activity: Design, Synthesis, Molecular Docking, and Mechanistic Studies

  2020cited by this paper
• Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.

  2020cited by this paper
• PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy

  2020cited by this paper
• New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation.

  2020cited by this paper
• Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles

  2020cited by this paper
• Novel benzimidazole derivatives as anti-cervical cancer agents of potential multi-targeting kinase inhibitory activity

  2020cited by this paper
• Discovery of N1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment.

  2019cited by this paper
• Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives

  2019cited by this paper
• Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.

  2019cited by this paper
• Thiazolidinediones: the Forgotten Diabetes Medications

  2019cited by this paper
• Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

  2019cited by this paper
• A novel synthesis, X-ray analysis and computational studies of (Z)-ethyl 2-((Z)-5-((dimethylamino)methylene)- 4-oxo-3-phenylthiazolidin-2-ylidene)acetate as a potential anticancer agent

  2019cited by this paper
• The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations

  2019cited by this paper
• Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents.

  2019cited by this paper
• Optimization of pyrrolizine-based Schiff bases with 4-thiazolidinone motif: Design, synthesis and investigation of cytotoxicity and anti-inflammatory potency.

  2019cited by this paper
• Thiazolidinones: Synthesis, Reactivity, and Their Biological Applications

  2019cited by this paper
• EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients

  2019cited by this paper
• Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations.

  2019cited by this paper
• A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients

  2019cited by this paper
• Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer

  2019cited by this paper
• Third generation EGFR TKIs: current data and future directions

  2018cited by this paper
• The functions and regulation of the PTEN tumour suppressor: new modes and prospects

  2018cited by this paper
• Thiazoles and Thiazolidinones as COX/LOX Inhibitors

  2018cited by this paper
• EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy

  2018cited by this paper
• Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

  2018cited by this paper

• Targeting EGFR with thiazolidin-4-ones: Structure-guided design, synthesis, and in silico profiling for anticancer drug discovery.

  2025cites this paper
• Identification of thiazolidin-4-one scaffold-based molecules as PI3Kα inhibitors: Molecular docking, MM/GBSA, IFD, ADMET, water-map analysis, and MD simulations

  2025cites this paper
• Design, synthesis, and in silico studies of new benzofuran–pyrazole hybrids as multi-kinase inhibitors with potential antiproliferative activity

  2025cites this paper
• Recent advances in Pyrazolo[3,4-d]pyrimidine-based dual inhibitors in the treatment of cancers.

  2025cites this paper